首页 News 正文

GlaxoSmithKline announced on December 11th that the European Commission has approved the use of Dostarlimab (Jemperli) in combination with carboplatin and paclitaxel for the treatment of primary advanced or recurrent endometrial cancer carrying mismatch repair defects (dMMR) or high microsatellite instability (MSI-H).
您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

穿越夜时空簿 新手上路
  • 粉丝

    0

  • 关注

    0

  • 主题

    3